Clinical trials: Stage I Skin Cancer
Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
The goal of this clinical research study is to learn if GSK2636771 given in combination with pembrolizumab can help to control the disease in patients with refractory (has not responded to treatment) metastatic melanoma.
- Trial name
- NCT03131908
- Testing
- GSK2636771, Pembrolizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease
RATIONALE: Collecting and storing samples of blood and tumor tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898508
- Testing
- gene expression analysis, mutation analysis, proteomic profiling
- Where
- 3 sites in United States
- Volunteers
- 563 people
- Sponsor
- City of Hope Medical Center
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
- Trial name
- NCT06726148
- Testing
- ECI830, ribociclib, fulvestrant
- Where
- 33 sites in United States, Australia and 14 more
- Volunteers
- 280 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.
To determine the effects of endurance exercise training on cardiopulmonary fitness in breast cancer patients undergoing neoadjuvant chemotherapy.
- Trial name
- NCT00405678
- Testing
- Exercise Training, Chemo only
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Duke University
HER2-positive Breast Cancer, Male Breast Cancer
Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
The purpose of this study is to look at the safety and immune response to a vaccine used in patients previously treated for HER2 (human epidermal growth factor receptor 2) positive breast cancer.
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT01632332
- Testing
- HER-2/neu peptide vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination…
- Conditions
- Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
- Trial name
- NCT06827236
- Testing
- BNT323, BNT327
- Where
- 81 sites in United States, Australia and 9 more
- Volunteers
- 380 people
- Sponsor
- BioNTech SE
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Reflects the Intervention (AI Chatbot)
The goal of this clinical trial is to investigate the impact of an AI-powered chatbot intervention on improving knowledge, attitudes, and empowerment in breast cancer patients.
- Trial name
- BC-CHAT (NCT06943911)
- Testing
- AI Chatbot for Breast Cancer Patient Education and Empowerment
- Where
- Egypt
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Mostafa Shaban
Breast Cancer, Cognitive/Functional Effects
Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCSG-1-98
RATIONALE: Studying cognitive function, such as thinking, attention, concentration, and memory, in postmenopausal women receiving hormone therapy for breast cancer may help improve quality of life and the ability to plan…
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Fatigue, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00343616
- Testing
- cognitive assessment, fatigue assessment and management, psychologic distress
- Where
- 12 sites in Australia, Belgium and 4 more
- Volunteers
- 135 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Sentinel Lymph Node Biopsy to Assess Axillary Lymph Nodes in Women With Stage I or Stage II Breast Cancer
RATIONALE: Diagnostic procedures such as sentinel lymph node biopsy may improve the ability to detect breast cancer and determine the extent of disease.
- Trial name
- NCT00005821
- Testing
- patent blue V dye, conventional surgery, lymphangiography
- Where
- 4 sites in United Kingdom
- Sponsor
- Royal Marsden NHS Foundation Trust
Melanoma
A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
This is a Phase I study combining vemurafenib and hydroxychloroquine in the treatment of BRAF V600E+ metastatic melanoma.
- Trial name
- NCT01897116
- Testing
- Hydroxychloroquine (HCQ), Vemurafenib (VEM)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer
RATIONALE: SU5416 may stop the growth of breast cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005822
- Testing
- doxorubicin hydrochloride, semaxanib, conventional surgery
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Case Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma (Skin)
Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
RATIONALE: Interferon alfa-2b may interfere with the growth of cancer cells. PURPOSE: Randomized phase III trial to study the effectiveness of interferon alfa-2b in treating patients who have melanoma with early lymph node…
- Trial name
- NCT00004196
- Testing
- recombinant interferon alfa, lymphangiography, Observation
- Where
- 4 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- University of Alabama at Birmingham
Breast Cancer
Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
RATIONALE: Androgens can cause the growth of breast cancer cells. Hormone therapy using dehydroepiandrosterone (DHEA) may fight breast cancer by blocking the use of androgen by the tumor cells.
- Trial name
- NCT00516542
- Testing
- letrozole, DHEA, pharmacological study
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- OHSU Knight Cancer Institute
Melanoma and Sarcoma
TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)
This study will look at the safety and effects of combining a new drug called Talimogene Laherparepvec (T-VEC) with chemotherapy delivered by Isolated Limb Perfusion (ILP).
- Trial name
- TITAN (NCT03555032)
- Testing
- Talimogene laherparepvec (T-VEC)
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer Stage I, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
CRYO-1: Cryoablation in Elderly Patients With Early-Stage Breast Cancer.
This study looks at a new way to treat early-stage breast cancer in older adults using a freezing technique called cryoablation.
- Trial name
- CRYO-1 (NCT07398118)
- Testing
- Cryoablation / Cryotherapy
- Where
- 3 sites in Netherlands
- Volunteers
- 61 people
- Sponsor
- St. Antonius Hospital
Breast Cancer
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00003418
- Testing
- exemestane, tamoxifen citrate
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 4,400 people
- Sponsor
- International Collaborative Cancer Group
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors
This clinical trial studies whether a navigation program improves survivorship support service participation among survivors of breast cancer that has not spread from where it first started (primary site) to other places in the…
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT07699991
- Testing
- Best Practice, Patient Navigation, Referral
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.